scholarly journals Significant usefulness of heart rate variabilities by ambulatory electrocardiographic monitoring in diabetes mellitus, congestive heart failure and ischemic heart disease.

1992 ◽  
Vol 12 (1) ◽  
pp. 14-23
Author(s):  
Akira Kurita ◽  
Hirokazu Nagayoshi ◽  
Takayuki Miyake ◽  
Yasuhiro Okamoto ◽  
Bonpei Takase
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Heart Rate ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
Electrocardiographic Monitoring

Heart rate variability in patients with diabetes mellitus, ischemic heart disease, and congestive heart failure

1992 ◽  
Vol 25 (2) ◽  
pp. 79-88 ◽  
Author(s):  
Bonpei Takase ◽  
Akira Kurita ◽  
Masayuki Noritake ◽  
Akimi Uehata ◽  
Toshiharu Maruyama ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Heart Rate ◽  
Congestive Heart Failure ◽  
Heart Rate Variability ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
Patients With Diabetes

scholarly journals Heart rate variability in patients with congestive heart failure and ischemic heart disease by Holter monitoring

1991 ◽  
Vol 17 (2) ◽  
pp. A190
Author(s):  
Hirokazu Nagayoshi ◽  
Akira Kurita ◽  
Bonpei Takase ◽  
Hiroyuki Hikita ◽  
Hideki Mitani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Congestive Heart Failure ◽  
Heart Rate Variability ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Holter Monitoring ◽  
Ischemic Heart

scholarly journals Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure.

1994 ◽  
Vol 84 (1) ◽  
pp. 20-28 ◽  
Author(s):  
L Bonneux ◽  
J J Barendregt ◽  
K Meeter ◽  
G J Bonsel ◽  
P J van der Maas
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
The Future

Outcome of Congestive Heart Failure, Dilated Cardiomyopathy, Hypertrophic Hyperkinetic Disease, and Ischemic Heart Disease in Dialysis Patients

1990 ◽  
Vol 10 (3) ◽  
pp. 213-221 ◽  
Author(s):  
Patrick s. Parfrey ◽  
Sheila M. Griffiths ◽  
John D. Harnett ◽  
Rhoda Taylor ◽  
Anthony King ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Dilated Cardiomyopathy ◽  
Ischemic Heart ◽  
Dialysis Patients

scholarly journals The Use of Selective Inhibitor of If-Channels Ivabradine in Patients with Ischemic Heart Disease, Heart Failure with High Heart Rate

Kardiologiia ◽  
2019 ◽  
Vol 59 (10) ◽  
pp. 60-65 ◽  
Author(s):  
Yu. N. Belenkov ◽  
I. S. Ilgisonis ◽  
Yu. I. Naymann ◽  
E. A. Privalova ◽  
A. V. Zhito
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Prognostic Significance ◽  
Left Ventricular ◽  
Ischemic Heart ◽  
Left Ventricular Ejection ◽  
High Heart Rate ◽  
Ventricular Ejection Fraction

Ischemic heart disease (IHD) and chronic heart failure (CHF) belong to leading causes of death among patients with cardiovascular diseases (CVD). Modern medical approaches to the treatment of patients with CHF do not always provide a significant improvement in the quality of life, a decrease in the frequency of CHF exacerbations and hospitalizations, and an improvement of the long-term prognosis. According to the neurohumoral theory of IHD and CHF development, the blockade of the sympathoadrenal system with β-adrenoblockers (β-AB) is pathogenetically substantiated, and preparations of this group are recommended as one of the main classes of drugs for the treatment of patients with CHF. However, selection of heart rhythm slowing therapy in patients with CHF of ischemic genesis is often difficult due to the development of undesirable side effects of β-AB, intolerance and/or due to the presence of contraindications for their use. Randomized studies have shown that prescribing a combination of β-AB and If-channel blocker ivabradine for heart rate (HR) reduction or solely ivabradine when use of β-AB is impossible in complex CHF therapy, improves the left ventricle (LV) diastolic function, reducing mortality from CHF decompensation. However, the prognostic significance of the use of ivabradine in patients with CHF with preserved left ventricular ejection fraction of ischemic genesis with heart rate higher than 70 beats/min receiving maximum tolerated doses of β-AB remains not fully investigated.

Sign in / Sign up

Export Citation Format

Share Document